Abstract
Human anti-murine antibody (HAMA) response is a serious problem in the repeated infusion of murine monoclonal antibodies (MoAbs). HAMA positive sera were obtained from seven patients with colorectal cancer, pancreas cancer, malignant melanoma or myocardial infarction who had previously received radiolabelled MoAbs. The nature of HAMA was analysed using size exclusion high performance liquid chromatography (HPLC) after incubating with radiolabelled MoAbs including IgG, Fab or human/mouse chimeric Abs. Immune complexes composed of HAMA and MoAbs were formed. The percentage of radioactivity with a high molecular weight was related to HAMA levels determined by enzyme linked immunosorbent assay. Most radioactivity present in immune complex shifted to the antibody fraction after the addition of normal murine serum. All of seven sera were reactive with all four murine IgGs and this suggests that HAMA in these patients recognised the constant region of MoAbs. In one patient, HAMA was considered to recognise the variable region and to be anti-idiotypic. There was no significant binding with human/mouse chimeric Abs in any HAMA positive serum, although five out of seven patients were reactive with murine MoAb Fab, indicating that HAMA was composed of Abs responsive to the CH1 or CL region of murine IgG. These results suggest that (1) HAMA was composed of Ab responsive to Fc portion and/or CH1 or CL region of murine IgG, and (2) human/mouse chimeric Abs look promising in the repeated infusion of MoAb in HAMA positive patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hosono, M., Endo, K., Sakahara, H. et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 65, 197–200 (1992). https://doi.org/10.1038/bjc.1992.41
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.41
This article is cited by
-
A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2
AMB Express (2022)
-
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
BioDrugs (2017)
-
Consensus on the treatment of pancreatic cancer in Spain
Clinical and Translational Oncology (2009)
-
Antibody therapy of non-Hodgkin's B-cell lymphoma
Cancer Immunology, Immunotherapy (2003)
-
Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer
Diseases of the Colon & Rectum (1998)